Clinical Trials Logo

Filter by:
NCT ID: NCT05231694 Recruiting - Ischemic Stroke Clinical Trials

The Impact of Electroacupuncture Combined With NGF on Clinical Effect and Functional Changes on Ischemic Stroke

Start date: April 1, 2022
Phase: Phase 4
Study type: Interventional

Ischemic stroke is a common clinical disease, often accompanied by motor dysfunction and cognitive impairment. At present, clinical treatment for patients with ischemic stroke recovery is limited and ineffective. The emergence of NGF has surprised the field of neurorehabilitation, but the clinical effect is not satisfactory. The main problem is that NGF is a macromolecular material with a molecular weight of 13.4 KD, which is difficult to penetrate the blood brain barrier. A large number of previous studies in our team have found that electroacupuncture with specific stimulation mode can open the blood brain barrier and induce NGF into the brain。Therefore, the purpose of this study is to investigate the effect of specific stimulation mode electroacupuncture combined with NGF treatment together with rehabilitation training on patients with ischemic stroke recovery period and to explore the mechanism of this combination therapy to improve brain function, which creates a new method and theoretical basis for nerve rehabilitation of integrated traditional Chinese and Western medicine.

NCT ID: NCT05231616 Recruiting - Deep Learning Model Clinical Trials

Deep Learning Model for Diagnosis and Contour of Cervical Lymph Node for Nasopharyngeal Carcinoma

Start date: January 5, 2021
Phase:
Study type: Observational

The diagnosis of cervical lymph node in nasopharyngeal carcinoma is difficult. Magnetic resonance imaging based deep learning model may be a noninvasive and rapid diagnostic method for cervical lymph node. Thus, the investigators aimed to develop and externally validate a deep learning model to assist in the diagnosis and localization of metastatic lymph nodes in nasopharyngeal carcinoma.

NCT ID: NCT05231382 Recruiting - Clinical trials for Hepatocellular Carcinoma

Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma

Start date: March 28, 2022
Phase: Phase 3
Study type: Interventional

Hepatic artery infusion chemotherapy (HAIC) have shown promising outcomes in patients with advanced hepatocellular carcinoma (HCC).In China, Oxaliplatin combined with 5-fluorouracil is commonly used in continuous hepatic arterial perfusion chemotherapy.But the 5-FU requiring a long infusion and Calcium folate is also needed to sensitize 5-FU. Moreover, 5-FU regimen was associated with a variety of adverse events, which limited its application in HAIC.Compared to 5-fluorouracil, raltetrexed is less toxic, has a stronger anti-tumor effect and can be administered in just two to three hours. However, the comparison of the two drugs in HAIC to treat advanced HCC has not been reported. In this study, we will evaluate the the progression-free survival(PFS)、objective response rate(ORR)、 disease vacancy rate(DCR)、overall survival (OS) and safety in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of Raltetrexed plus oxaliplatin (SALOX) compared with oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment by designing prospective, multi-center phase III clinical study.

NCT ID: NCT05230719 Recruiting - Clinical trials for Acute Coronary Syndrome

Decrease Artery Occlusion by Distal Radial Arterial Cannulation, Observational Study

DONATION-OB
Start date: January 1, 2019
Phase:
Study type: Observational

The site of arterial access for coronary angiography and intervention has been the focus of research for decades as it is the source of major complications. Transradial access (TRA) reduces complications among patients undergoing percutaneous coronary procedures but is reported with the complication of radial artery occlusion (RAO) that limits the radial artery for future needs. Distal radial access (dTRA) has recently gained global popularity as an alternative access route for vascular procedures. Among the benefits of dTRA are the low risk of entry site bleeding complications, the low rate of radial artery occlusion, and improved patient and operator comfort. This study aims to reveal the feasibility and safety of dTRA and routine TRA procedures in acute coronary syndrome patients. The primary endpoints are forearm radical occlusion rate and major adverse cardiovascular events (MACEs) in the two groups. Investigators conduct this retrospected analysis to demonstrate the difference of the two procedure of Cannulation.

NCT ID: NCT05230537 Recruiting - Clinical trials for Age-Related Macular Degeneration

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Start date: February 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.

NCT ID: NCT05230381 Recruiting - Meningioma Clinical Trials

Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

Intra-operative blood loss of huge meningioma resection patients on average was over 1000ml. Intra-operative massive hemorrhage was associated with longer hospital of stay, higher expense, and higher mortality. Previous studies indicated intra-operative tranexamic acid infusion would decrease blood loss for cardiac, trauma and obstetric procedures. However, limited researches focusing on the effect of tranexamic acid in neurosurgery population, with heterogenous pathologies. The purpose of this study was to investigate the effect of tranexamic acid on intra-operative blood loss in patients undergoing huge meningioma resection.

NCT ID: NCT05230017 Recruiting - Clinical trials for Anti Phospholipid Syndrome

Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks

CAPSTONE
Start date: October 1, 2022
Phase:
Study type: Observational

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in patients with persistently positive antiphospholipid antibodies (aPLs). However, large-scale research on general population with persistent aPLs has been lacking. This project proposes to establish the first multicenter cohort of patients with persistently positive aPLs in China and conduct a comprehensive clinical phenotyping study. Based on traditional phenotypes of thrombotic and pregnancy events, the focus will be on extra-standard clinical phenotypes and prospective assessment of event risk and prognosis in aPL-positive population. A prospective analysis of extra-standard antibodies will also be conducted to recommend detection criteria for extra-standard antibody application in China and to assess their clinical significance.

NCT ID: NCT05229809 Recruiting - Gastric Carcinoma Clinical Trials

Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Yiqi Wenyang Jiedu prescription for postoperative gastric cancer.

NCT ID: NCT05229497 Recruiting - Clinical trials for Advanced Malignant Tumors

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Start date: May 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors

NCT ID: NCT05229328 Recruiting - Sepsis Clinical Trials

Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis

Start date: October 26, 2021
Phase:
Study type: Observational

Sepsis is a clinical syndrome with high morbidity and high fatality rate in emergency department. Patients with acute liver or kidney injury are more likely to develop Multiple Organ Dysfunction Syndrome(MODS) secondary to the non-hepatic injury group, and the prognosis deteriorates significantly. At present, there is no unified diagnostic criteria for acute liver injury associated with sepsis, and the commonly used prognostic evaluation system is rarely included in liver injury indicators, which is not good for practicality.